Lyell Immunopharma updated its Phase 1 trial of LYL273, a CAR T-cell therapy for relapsed or refractory metastatic colorectal cancer, showing gastrointestinal prophylaxis significantly reduced severe diarrhea and colitis from 55% to 10%. No severe cytokine release syndrome or neurotoxicity was observed under the new safety plan. The trial has been amended to a Phase 1/2 design to allow seamless expansion into a pivotal Phase 2 trial, including new cohorts for second-line treatment and combination with radiotherapy. Additional clinical data and an FDA End-of-Phase 1 meeting are expected in late 2026, advancing LYL273's development with Fast Track designation from the FDA.
McEwen Inc. announced a Pre-Feasibility Study (PFS) for its Grey Fox Project near Timmins, Ontario, projecting a 15-year mine life extension to 2041 and significant gold production growth at the Fox Complex. The project aims to increase annual gold o...
Heineken N.V. has repurchased a total of 3,535,760 shares under the second €750 million tranche of its €1.5 billion share buyback program as of June 5, 2026. The shares were bought both on the exchange and from Heineken Holding N.V., with an average ...
Lixiang Education Holding Co., Ltd. announced it has regained compliance with Nasdaq's minimum market value of publicly held shares requirement, reaching at least $5 million for 10 consecutive business days from May 21 to June 4, 2026. This follows a...
Credit Agricole Loire Haute-Loire has announced the publication of its social shares prospectus, approved by the French financial regulator AMF under approval number 26-181. The prospectus is available on the regional bank's website and provides deta...
US stock futures showed mixed performance with the Nasdaq 100 and S&P 500 gaining slightly while the Dow Jones fell, following recent market declines and amid rising geopolitical tensions between Israel and Iran. Investors are closely monitoring upco...
